Navigation Links
Ambry Genetics Announces Launch of Their CancerArray™ Product and Services Utilizing aCGH Technology

ALISO VIEJO, Calif., Aug. 31, 2011 /PRNewswire/ -- Ambry Genetics today introduces their new CancerArray™ product and services utilizing aCGH technology.  The Ambry CancerArray™ is a high resolution exon-focused 180K array offering genome-wide probe coverage with higher probe density coverage in over 400 known cancer-associated genes. The array enhances the resolution in these functionally important cancer regions.


"The CancerArray™ is a novel product for oncology-based researchers who want to detect genome-wide copy number variants with enhanced single-gene resolution in cancer associated regions," said Ardy Arianpour, Ambry's Vice President of Business Development. "We expect to see high demand and use of our CancerArray™ due to the increasing amount of translational oncology research being conducted by biotech and pharmaceutical companies and academic research groups."

The Ambry CancerArray™ is a comprehensive high resolution chromosome analysis approach to detect copy number variants without the need and additional cost for independent traditional karyotyping or single gene deletion/duplication analysis. The Ambry CancerArray™ utilizes aCGH technology to cover the entire genome at an average resolution of 20 kb.  The 180K CancerArray™ also offers increased coverage in over 400 known cancer-associated genes to further enhance the resolution in these functionally important regions.

"The enhanced CancerArray™ content is partially based on the Wellcome Trust Sanger Cancer Gene Census," explained Dr. Anja Kammesheidt, Ambry's Chief Scientific Officer. "The Ambry CancerArray™ will not only detect large copy number changes, but simultaneously will identify very small aberrations, near the single-exon level, in the most important cancer genes associated with germline and somatic variations."

The Ambry CancerArray™ is now ready to be ordered and processed for research purposes. For more information on the CancerArray™ and the full line of Ambry's genomic products and services, please visit our website at

About Ambry Genetics

Ambry Genetics is a CAP-accredited and CLIA-certified commercial clinical laboratory with headquarters in Aliso Viejo, California. Since the company's inception in 2000, it has become a leader in providing genetic services focused on clinical diagnostics and genomic services. Ambry has established a solid reputation for unparalleled service, and has been at the forefront of applying new technologies to the clinical molecular diagnostics market and to the advancement of disease research. To learn more about testing and services available through Ambry Genetics, visit

SOURCE Ambry Genetics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambry Genetics Announces Launch of Their StemArray(TM) Product and Services for High Resolution Characterization of Human Stem Cells
2. Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects
3. Ambry Genetics and RainDance Technologies Announce Partnership for Diagnostics and Genomics Services Utilizing the RDT 1000 for Sequence Enrichment and Targeted Resequencing Validation
4. Ambry Genetics Introduces AmbryScreen(TM), a Genetic Test Screening for Some of the Most Common and Severe Genetic Disorders Affecting Newborns.
5. Ambry Genetics Announces the Addition of Illumina HiSeq 2000 and First 510(K) Approved BeadXpress® to Its Sequencing and Genotyping Capabilities
6. Ambry Genetics Becomes First Certified Service Provider in US for NimbleGen SeqCap EZ Exome
7. Ambry Genetics Launches Illumina HiSeq 2000 Next Generation Sequencing Services
8. RainDance Technologies and Ambry Genetics Expand Collaboration to Address ADME Analysis
9. LABS, Inc. Announces Alliance with Ambry Genetics to Expand Testing Solutions for the Reproductive Health Industry
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 - Will ... Medical Education (CME) --> - Will ... Continuing Medical Education (CME) --> ... Continuing Medical Education (CME) ... products and services, will feature latest diagnostic imaging textbooks and decision ...
(Date:11/25/2015)... 25, 2015 Research and Markets ( ... Market - Global Forecast to 2020" report to ... accounting for 37.21% of the total market share in ... region is projected to growth at the highest ... attributed primarily to the fast growing water, industrial gas ...
(Date:11/25/2015)... --> --> ... für das Patent über eine neue Hepatitis-B-Behandlung, welches sie ... an Enyo Pharma vergeben haben. Im Rahmen ... und von Edelris gemeinsam mit seinen Partnern Inserm und ... HBV identifiziert, und es wurden neue Inhaltsstoffe entdeckt, die ...
Breaking Medicine Technology:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... of philanthropic seniors, is resulting in a way for homeless people to have ... Schaumburg have launched a new initiative whereby they are repurposing plastic bags into ...
(Date:11/25/2015)... ... 2015 , ... Many people know of the common symptoms of low thyroid ... skin. But many people who find their cholesterol levels and weight are creeping up ... especially if they don’t have any of the other symptoms. , Thyroid hormone plays ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... Tuberous Sclerosis Complex (TSC), as well as raising public awareness of the disorder ... need it—presented a third donation of $35,000 to bolster progress at the Tuberous ...
(Date:11/25/2015)... ... ... Since its launch in 2012, the Regenestem brand ( ... to patients with chronic degenerative medical conditions. Now, the U.S. Patent and Trademark ... Organizations are required to hold a registered trademark in order to make licensing ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to ... of the Create Real Impact awards. California Casualty is proud to support ... tide of distracted and reckless driving, the number one killer of young drivers. ...
Breaking Medicine News(10 mins):